JP2006514546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514546A5 JP2006514546A5 JP2004553781A JP2004553781A JP2006514546A5 JP 2006514546 A5 JP2006514546 A5 JP 2006514546A5 JP 2004553781 A JP2004553781 A JP 2004553781A JP 2004553781 A JP2004553781 A JP 2004553781A JP 2006514546 A5 JP2006514546 A5 JP 2006514546A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- seq
- composition
- organism
- complementary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42626902P | 2002-11-14 | 2002-11-14 | |
| PCT/US2003/036614 WO2004046327A2 (en) | 2002-11-14 | 2003-11-14 | Inhibitory oliogonucleotides targeted to bcl-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006514546A JP2006514546A (ja) | 2006-05-11 |
| JP2006514546A5 true JP2006514546A5 (https=) | 2006-12-28 |
Family
ID=32326325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004553781A Pending JP2006514546A (ja) | 2002-11-14 | 2003-11-14 | Ｂｃｌ−２を標的とする抑制性オリゴヌクレオチド |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7256284B2 (https=) |
| EP (1) | EP1572970A4 (https=) |
| JP (1) | JP2006514546A (https=) |
| AU (1) | AU2003295561A1 (https=) |
| CA (1) | CA2505680A1 (https=) |
| WO (1) | WO2004046327A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7498315B2 (en) * | 2004-06-01 | 2009-03-03 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| CA2631677C (en) * | 2005-12-01 | 2014-08-12 | Pronai Therapeutics, Inc. | Amphoteric liposome formulation |
| WO2009071681A2 (en) * | 2007-12-07 | 2009-06-11 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of bcl-2 |
| TW201019969A (en) * | 2008-11-17 | 2010-06-01 | Enzon Pharmaceuticals Inc | Branched cationic lipids for nucleic acids delivery system |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5831066A (en) | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
| US5734033A (en) * | 1988-12-22 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Antisense oligonucleotides inhibiting human bcl-2 gene expression |
| US5605798A (en) * | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| US5912147A (en) * | 1996-10-22 | 1999-06-15 | Health Research, Inc. | Rapid means of quantitating genomic instability |
| US6041181A (en) * | 1997-07-23 | 2000-03-21 | International Business Machines Corporation | Method of, system for, and computer program product for providing quick fusion in WHERE constructs |
| US7704962B1 (en) * | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
| CA2324440A1 (en) | 1998-03-28 | 1999-10-07 | University Of Utah Research Foundation | Directed antisense libraries |
| CA2365984A1 (en) | 1999-04-08 | 2000-10-19 | Oasis Biosciences, Inc. | Antisense oligonucleotides comprising universal and/or degenerate bases |
| US6310047B1 (en) | 1999-08-24 | 2001-10-30 | Virginia Commonwealth University | High affinity DNA binding compounds as adjuvants in antisense technology |
| US7056653B2 (en) | 2000-02-10 | 2006-06-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Detection of binding of charged species using PH- or potential-sensitive probes |
| US7795232B1 (en) * | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| AU2002241952A1 (en) | 2001-01-22 | 2002-07-30 | Genta Incorporated | Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers |
-
2003
- 2003-11-14 EP EP03786757A patent/EP1572970A4/en not_active Withdrawn
- 2003-11-14 CA CA002505680A patent/CA2505680A1/en not_active Abandoned
- 2003-11-14 WO PCT/US2003/036614 patent/WO2004046327A2/en not_active Ceased
- 2003-11-14 JP JP2004553781A patent/JP2006514546A/ja active Pending
- 2003-11-14 AU AU2003295561A patent/AU2003295561A1/en not_active Abandoned
- 2003-11-14 US US10/714,310 patent/US7256284B2/en not_active Expired - Fee Related
-
2007
- 2007-07-12 US US11/827,995 patent/US20080096835A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3472362B1 (en) | Papd5 and papd7 inhibitors for treating an hepatitis b infection | |
| JP2002272489A5 (https=) | ||
| RU2005133711A (ru) | Антисмысловые олигонуклеотиды (odn) к smad7 и их применение в области медицины | |
| JP2009532392A5 (https=) | ||
| RU2006126643A (ru) | Олигомерные соединения для модуляции bcl-2 | |
| CA2526893A1 (en) | Inhibition of the expression of huntingtin gene | |
| WO1994024144A3 (en) | Enhanced triple-helix and double-helix formation with oligomers containing modified purines | |
| JP2004511201A5 (https=) | ||
| JP2021500016A5 (https=) | ||
| BR112020020220A2 (pt) | Uso de inibidores da fubp1 para o tratamento de infecção pelo vírus da hepatite b | |
| WO1994012633A1 (en) | Stable oligonucleotides | |
| Bailly et al. | The influence of the 2‐amino group of guanine on DNA conformation. Uranyl and DNase I probing of inosine/diaminopurine substituted DNA. | |
| WO2003042385A2 (en) | Gene silencing using sense dna and antisense rna hybrid constructs | |
| RU2008125041A (ru) | миРНК ПРОТИВ МИОЗИНА VA И ДЕПИГМЕНТАЦИЯ КОЖИ | |
| CN112534055A (zh) | 用于调节rtel1表达的寡核苷酸 | |
| JP2006514546A5 (https=) | ||
| JPH11514220A (ja) | キメラオリゴヌクレオチド及びアンチセンス結合部位の確認におけるそれらの使用 | |
| Greber-Platzer et al. | Evidence against the current hypothesis of “gene dosage effects” of trisomy 21: ets-2, encoded on chromosome 21” is not overexpressed in hearts of patients with Down syndrome | |
| WO2001060998A3 (en) | Small oligonucleotides with anti-tumor activity | |
| JP7813254B2 (ja) | Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド | |
| KR101783444B1 (ko) | miR-33-5p 를 이용한 뇌신경세포 보호 물질 스크리닝 방법 | |
| JP2007104971A (ja) | ミオスタチンのスプライシング制御アンチセンスオリゴヌクレオチド | |
| JP2008503569A5 (https=) | ||
| WO2004046327A3 (en) | Inhibitory oliogonucleotides targeted to bcl-2 | |
| EP1073731B1 (en) | Nucleic acid enzyme for rna cleavage |